Tirosint is the first and only levothyroxine therapy in liquid gel cap form.
Tirosint gel caps are pure. They contain only T4, water, glycerin, and gelatin. In addition:
• The PearlTec™ PureDelivery Matrix™ process avoids excessive heat, preventing
degradation of the molecule during manufacturing by heat-related deactivation of T41
• The gel cap shell protects T4 from degradation by light, air, humidity, and micro-
contaminants,1,2 assuring levothyroxine stability and consistency over time
Importantly, dissolution of Tirosint in the presence of gastric pH was also recently evaluated. This in vitro study revealed that Tirosint, regardless of the level of gastric pH, dissolved rapidly and consistently. (It is important to note that in vitro data do not necessarily correlate with clinical outcomes.)
Tirosint is also conveniently packaged, with blister packs that are color coded and clearly marked for daily dosing. Tirosint is also available in 10 dosage strengths, including an exclusive 13 microgram dose.
Tirosint is unique and has no generic substitute. Be sure to add “Dispense as Written” to your prescription so your patients get the precision and consistency of Tirosint.
Tirosint is administered as a single daily dose, preferably one-half to one-hour before breakfast. Tirosint should be taken at least 4 hours apart from drugs that are known to interfere with its absorption. Tirosint capsules cannot be cut or crushed. Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.
Tirosint should be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).
Tirosint soft gel capsules should be protected from light and moisture.
Unlike levothyroxine sodium tablets, Tirosint capsules cannot be cut or crushed.
References: 1. Data on file, 2002, Akrimax Pharmaceuticals, LLC. 2. Data on file, 2006, Akrimax Pharmaceuticals, LLC. 3. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105-110.